Finance

Ganite maker reports reaching major corporate milestones in third quarter

Published in Medical Letter on the CDC and FDA, November 30th, 2003

Genta, Inc., (GNTA) announced financial results for the third quarter of 2003, a period that has been marked by significant milestones in the company's history.

These achievements included:

1) U.S. Food and Drug Administration (FDA) approval and launch of Ganite (gallium nitrate injection), Genta's first commercial product

2) Announcement of positive results from the company's phase III trial with Genasense (oblimersen sodium) for the treatment of patients with advanced malignant melanoma

3) Initiation of a "rolling" new drug application (NDA) submission to the FDA for Genasense in advanced malignant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry